Catalyst Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>CB</div>
CBIO -- USA Stock  

USD 6.19  0.48  8.41%

36% of stocks are less volatile than Catalyst, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. While many risk-averse institutional investors are getting carried away by overanalyzing healthcare space, it is reasonable to outline Catalyst Biosciences. We will cover the possibilities of Catalyst Biosciences' current volatility to continue through December.
Published over a month ago
View all stories for Catalyst Biosciences | View All Stories
Will institutional investors take over Catalyst Biosciences December?
The entity currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest Catalyst Biosciences is not taking enough advantage from borrowing. The firm has a current ratio of 8.7, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Volatility is a rate at which the price of Catalyst Biosciences or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Catalyst Biosciences may increase or decrease. In other words, similar to Catalyst's beta indicator, it measures the risk of Catalyst Biosciences and helps estimate the fluctuations that may happen in a short period of time. So if prices of Catalyst Biosciences fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is Catalyst Biosciences's Liquidity

Catalyst Biosciences financial leverage refers to using borrowed capital as a funding source to finance Catalyst Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Catalyst Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Catalyst Biosciences's total debt and its cash.

How Catalyst utilizes its cash?

To perform a cash flow analysis of Catalyst Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catalyst Biosciences is receiving and how much cash it distributes out in a given period. The Catalyst Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Catalyst Biosciences Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (44.76 Million)

Catalyst Biosciences Volatility Drivers

Catalyst Biosciences unsystematic risk is unique to Catalyst Biosciences and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Catalyst Biosciences you can also buy DYADIC INTERNATIONAL INC. You can also mitigate this risk by investing in the biotechnology sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Catalyst Biosciences important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Catalyst Biosciences income statement and balance sheet. Here are more details about Catalyst volatility.